Dengue Envelope-2 14 kDa
Sterile filtered colorless solution.
Greater than 95% as determined by SDS-PAGE.
Description
Recombinant Dengue Envelope 2 produced in E. coli is a single polypeptide chain containing 126 amino acids (aa 298-400) and having a molecular mass of 13.8kDa. Recombinant Dengue Envelope 2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques
Product Specs
MGSSHHHHHH SSGLVPRGSH MGSSYSMCTG KFKVVKEIAE TQHGTIVIRV QYEGDGSPCK IPFEIMDLEK RHVLGRLITV NPIVTEKDSP VNIEAEPPFG DSYIIIGVEP GQLKLNWFKK GSSIGQ.
Product Science Overview
Dengue virus (DENV) is a member of the Flaviviridae family, which includes several medically significant viruses. It is responsible for causing dengue fever (DF) and dengue hemorrhagic fever (DHF), affecting millions of people worldwide annually . The virus is transmitted through the bites of infected Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus .
The dengue virus encodes three structural proteins: the capsid ©, membrane (M), and envelope (E) proteins, along with seven non-structural proteins . The envelope protein (E) plays a crucial role in the virus’s ability to attach to and enter host cells . It is also the primary target for neutralizing antibodies, making it a key focus for vaccine development and diagnostic tools .
The envelope protein 2 (E2) of the dengue virus type 2 (DENV-2) is particularly significant due to its role in mediating the virus’s attachment to host cells and its interaction with the immune system . The E2 protein consists of several domains that facilitate these interactions, including specific loops that bind to cell surface receptors .
Recombinant technology allows for the production of the dengue virus envelope 2 protein in a laboratory setting. This involves inserting the gene encoding the E2 protein into a suitable expression system, such as bacteria or yeast, to produce large quantities of the protein . Recombinant E2 proteins are used in various applications, including vaccine development, diagnostic assays, and research into the virus’s structure and function .
- Vaccine Development: The recombinant E2 protein is a critical component in the development of dengue vaccines. By eliciting an immune response against the E2 protein, vaccines can potentially provide protection against dengue virus infection .
- Diagnostic Tools: Recombinant E2 proteins are used in diagnostic assays to detect dengue virus infections. These assays can identify antibodies against the E2 protein in patient sera, aiding in the diagnosis of dengue fever .
- Structural Studies: Research into the structure of the E2 protein helps to understand how the virus interacts with host cells and the immune system. This knowledge is essential for designing effective vaccines and antiviral therapies .
